Biosimilars are pharmaceutical versions of biologic compounds that are highly similar or identical to older biologic drugs. These copies of biologics can be made by companies approved to make generic versions of biologic drugs so that patients and health care providers have lower-cost options when their original medication becomes expensive or unavailable.
Biosimilars are produced with the same process as the original biologic drug, but they are not the same exact molecule. This means that they have the same side effects and strengths of the original drug. But often, their molecular structure is very similar to their originally-produced version. Biosimilars are intended to substitute the current reference product in the basic and expanded formulary. They have the same indications, contraindications and side effects at the same doses as their reference product. A good example is Nexavar® (sorafenib).
Highlighted with 89 tables and 90 figures, this 180-page report “Global Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global biosimilars market and all its sub-segments through extensively detailed classifications.
Global biosimilars market will reach $113.25 billion by 2030, growing by 25.7% annually over 2020-2030 driven by the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent expirations of many blockbuster drugs, and better healthcare provisions.
Request Research Sample with Latest Industry Insights (270+ Pages Report): https://altusmarketresearch.com/reports/sample/29834
Based on Product Type, the global Biosimilars Market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
• Recombinant Non-glycosylated Biosimilars
o Insulin
o Recombinant Human Growth Hormone (rHGH)
o Granulocyte Colony Stimulating Factor
o Interferon
• Recombinant Glycosylated Biosimilars
o Monoclonal Antibodies (mAb)
o Erythropoietin (EPO)
o Follicle Stimulating Hormone
• Recombinant Peptides and Others
o Tumor Necrosis Factor (TNF)-Inhibitor
o Parathyroid Hormone
o Enzymes, Immunomodulators, GnRH Analogs and Others
Based on Indication, the global Biosimilars Market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
• Cancer
• Autoimmune Disease
• Blood Disorder
• Diabetes
• Growth Hormone Deficiency
• Infectious Diseases
• Other Indications
Based on Manufacturing, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
• Contract Manufacturing
• Inhouse Manufacturing
Based on End User, the global Biosimilars Market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
• Hospitals and Clinics
• Research Institutes
• Other End Users
Geographically, the following regions together with the listed national/local markets are fully investigated:
• North America (U.S., Canada, and Mexico)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (Turkey, Iran, South Africa)
For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Product Type, Indication, and End User over the forecast years are also included.
Key Players (this may not be a complete list and extra companies can be added upon request):
AMEGA Biotech S.A.
Apotex Inc.
Biocon Ltd
Biogen Inc.
Boehringer Ingelheim
Celltrion, Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
Intas Pharmaceuticals Ltd.
LG Chem, Ltd.
Merck and Co. Inc.
Mylan N.V.
Pfizer Inc.
Samsung Biologics Co., Ltd.
Sandoz International GmbH
STADA Arzneimittel AG
Teva Pharmaceutical Industries Ltd.
